Biogen drug to get FDA review for new use
Milwaukee Business Journal - Milwaukee,WI,USA
Biogen Idec Inc. said Tuesday two FDA panels will jointly review its Tysabri multiple sclerosis drug as a potential treatment of Crohn's disease. ...
See all stories on this topic

BSS Group FY07 Profit Rises, Revenue Up 17.2% - Update
RTT News - Williamsville,NY,USA
The sBLA also included data from more than 1500 CD patients treated with Tysabri, as well as proposed labeling and a risk management plan. ...
See all stories on this topic

TechMARK movers: iSOFT deal in jeopardy
ShareCast - London,UK
... and American drug maker Biogen Idec said two US Food and Drug Administration (FDA) committees will review Tysabri for the treatment of Crohn's disease. ...
See all stories on this topic

DJ MARKET COMMENT: London Stocks Trade Higher
Onet.pl - Poland
Tysabri is a humanized monoclonal antibody believed to block entry of inflammatory immune cells into the wall of the intestine, thus limiting inflammatory ...
See all stories on this topic

ISEQ down in morning trade
Irish Examiner - Cork,Ireland
Tysabri is also intended for use for multiple sclerosis patients. There were some moves upwards also on this morning's ISEQ - Kerry Group was up 10c while ...
See all stories on this topic

FDA to review Tysabri for the treatment of Crohn's disease
Pharmaceutical Business Review - USA
Elan Corporation and Biogen Idec have revealed that two of the FDA's advisory committees will review their Tysabri drug for the treatment of Crohn's disease ...
See all stories on this topic

FDA panel set to decide on expanded use for Tysabri
BiopharmaReporter.com - Montpellier,France
Novartis' oral Fingolimod (FTY720) is tipped to represent the most highly anticipated pipeline drug since the initial launch of Tysabri. ...
See all stories on this topic